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Abstract
Objectives: Cognitive remediation therapy (CRT) may benefit people with bipolar 
disorder type I and II for whom cognitive impairment is a major contributor to disabil-
ity. Extensive research has demonstrated CRT to improve cognition and psychosocial 
functioning in people with different diagnoses, but randomised trials of evidenced 
therapy programmes are lacking for bipolar disorders. The Cognitive Remediation in 
Bipolar (CRiB) study aimed to determine whether an established CRT programme is 
feasible and acceptable for people with bipolar disorders.
Methods: This proof-of-concept, single-blind randomised trial recruited participants 
aged 18-65 with bipolar disorder, not currently experiencing an episode. They were 
1:1 block randomised to treatment-as-usual (TAU) with or without individual CRT for 
12 weeks. The partly computerised CRT programme (“CIRCuiTS”) was therapist-led 
and is evidence-based from trials in those with psychotic illnesses. Data were col-
lected and analysed by investigators blinded to group allocation. The main outcomes 
(week 13 and 25) examined participant retention, intervention feasibility and puta-
tive effects of CRT on cognitive and psychosocial functioning via intention-to-treat 
analyses. Trial registration: ISRCTN ID32290525.
Results: Sixty participants were recruited (02/2016-06/2018) and randomised to 
CRT (n = 29) or TAU (n = 31). Trial withdrawals were equivalent (CRT n = 2/29; TAU 
n = 5/31). CRT satisfaction indicated high acceptability. Intention-to-treat analyses 
(N = 60) demonstrated greater improvements for CRT- than TAU-randomised partici-
pants: at both week 13 and 25, CIRCuiTS participants showed larger improvements 
in the following domains (week 25 effect sizes reported here): IQ (SES = 0.71, 95% 
CI [0.29,1.13]), working memory (SES = 0.70, 95% CI [0.31,1.10]), executive func-
tion (SES = 0.93, 95% CI [0.33,1.54]), psychosocial functioning (SES = 0.49, 95% CI 
[0.18,0.80]) and goal attainment (SES = 2.02, 95% CI [0.89,3.14]). No serious adverse 
events were reported.
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1  | INTRODUC TION
Bipolar disorder (BD) is common, complex, and often inadequately 
treated: calls have begun to pursue evidence-based therapies that 
target fundamental cognitive process1 since two thirds of patients 
suffer cognitive deficits which are often pronounced and widespread 
(spanning memory, attention, and executive functions), persisting 
throughout periods of recovery and directly linked to psychosocial 
and occupational functioning impairments.2 As well as functional 
impacts, a pattern of cognitive deterioration may increase episode 
recurrence, so improving cognitive abilities might enhance not only 
short-term wellbeing but potentially the future course of the disor-
der.1,3,4 Cognitive Remediation Therapy (CRT) is a psychological in-
tervention that has demonstrated reliable benefits for people with 
schizophrenia, improving core cognitive functioning, daily function-
ing, and quality-of-life as determined through extensive examination 
via clinical trials (efficacy, effectiveness, mechanistic) and compre-
hensive meta-analytic syntheses.eg5-7 There are well-documented 
similarities between the cognitive difficulties experienced by people 
with schizophrenia and bipolar disorder: they appear comparable in 
terms of impact and quality, although are on average less severe for 
patients with BD than schizophrenia and there is less evidence of a 
premorbid component.8 Preliminary evidence for the potential ben-
efits of CRT for BD is encouraging: an initial meta-analysis found 
analogous cognitive effects in trials including some participants with 
affective disorders (ES = 0.44) compared to those only assessing in-
dividuals with psychotic disorders (ES = 0.36).7 A handful of small 
or non-randomised studies have ensued, recently synthesised in 
systematic reviews3,4 reporting only two published randomised tri-
als of CRT (one for those with psychotic bipolar disorder,9 the other 
employing a short-term group therapy paradigm for a small sample 
of patients with BD10) concluding that individual CRT provided more 
intensively or for a longer duration might demonstrate meaningful 
benefits.
We present here the findings of a randomised proof-of-concept 
trial (the “CRiB” study) comparing an evidence-derived, intensive, in-
dividual manualised CRT intervention with treatment-as-usual. The 
CRiB trial aimed to determine the potential for CRT development 
into a new evidence-based therapy for bipolar disorder (type I and 
II) by investigating four primary outcomes: whether an established 
therapist-led CRT programme is 1) feasible and 2) acceptable for this 
patient group and whether it yields benefits in comparison to usual 
care, in terms of 3) improved cognitive performance and 4) improved 
psychosocial functioning.
2  | MATERIAL S AND METHODS
2.1 | Study design
This was a single-blind, proof-of-concept randomised trial conducted 
in one UK centre within an academic clinical research facility (South 
London & Maudsley NHS Trust and King's College London). The trial 
protocol contains full details of the study methodology.11 The authors 
assert that all procedures contributing to this work comply with the 
ethical standards of the relevant national and institutional commit-
tees on human experimentation and with the Helsinki Declaration of 
1975, as revised in 2008. All procedures involving human subjects/pa-
tients were approved by City Road & Hampstead UK Research Ethics 
Committee (16/10/2015, reference 15/LO/1557).
2.2 | Participants
Participants were eligible if they had a diagnosis of BD, were cur-
rently euthymic, aged 18-65 years without meeting exclusion cri-
teria (not being able to communicate in English, not being able to 
use a computer, have a substantial neurological illness, substance-
use, or personality disorder). No other eligibility restrictions were 
placed on somatic illnesses or medications taken either upon trial 
entry or medication changes throughout participation, in line with 
usual care. However, we did ask patients whether they were un-
dergoing a psychological therapy at present or planning any treat-
ment changes in the near future and if so, delayed screening for 
study eligibility. Current euthymia was defined as scoring <8 on the 
Hamilton Rating Scale for Depression (HAMD)12 and Young Mania 
Rating Scale (YMRS)13 on two occasions one week apart assessing 
mood over the preceding month. Eligibility, including diagnosis, was 
assessed by trained researchers (DT, TM, RS) and validated by a psy-
chiatrist (NY, KM, AHY). Participants were recruited via secondary 
and primary care services as well as off- and on-line advertisement 
from the community. Written informed consent was obtained from 
all individuals before participating, following full explanations of the 
procedures involved.
2.3 | Randomisation and masking
Participants were assigned to receive CRT in addition to treatment-
as-usual (TAU) or TAU alone following completion of the baseline 
Conclusions: CRT is feasible for individuals with bipolar disorders and may enhance 
cognition and functioning. The reported effect sizes from this proof-of-concept trial 
encourage further investigation in a definitive trial.
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assessment (week 0). A 1:1 block allocation design with random 
and variable block size was generated by an independent, validated 
web-based randomisation system including concealed sequence 
allocation and locked randomisation details after allocation, as 
detailed in the protocol.11 Randomisation was stratified by the in-
tensity of TAU as assessed by the Client Service Receipt Inventory 
(CSRI) service-use assessment14 (intensive or non- intensive TAU, 
defined respectively as more or less than monthly appointments 
with a healthcare professional). Investigators responsible for ob-
taining informed consent and undertaking data collection (includ-
ing symptoms, functioning, and cognitive outcome ratings; DT/
TM) were blinded to group allocation; the trial statistician (JH) was 
also blinded. To maintain investigator blinding, the unblinded trial 
coordinator (RS) carried out randomisation, conveyed allocation 
by telephone or in person to therapists and participants, request-
ing for participants to not disclose their group allocation to data 
collectors. Those delivering and receiving CRT intervention were 
unblinded out of necessity.
2.4 | Intervention
Over 12 weeks, CRT was delivered by trained postgraduate psy-
chologists with supervision from clinical psychologists with >5 years 
CRT experience. The metacognition-informed, therapist-led, com-
puterised CRT program “CIRCuiTS” emphasises strategy use and 
transfer having been established in populations diagnosed with 
psychoses6,15,16; In addition to compensatory (or strategy-based) 
remediation approaches, all session formats also included a restora-
tive remediation element (eg, “drill and practice” of cognitive tasks 
that were clearly distinct from cognitive outcome assessments). CRT 
flexibly utilised a combination of formats (in-person, telephone, and 
individual practice sessions) which were arranged under the respon-
sibility of the therapist, accommodating the patients’ needs. Target 
engagement comprised three sessions per week including at least 
one session guided by the therapist each week, with a target total 
of 20-30 hours. The minimum dose of 20 hours was proposed fol-
lowing evidence in schizophrenia research.16 Appendix A contains 
additional details.
2.5 | Procedures
As detailed in the protocol,11 all participants continued receiving 
usual care throughout the trial. After baseline assessment and 
randomisation (week 0), the 12-week intervention period com-
prised of CRT + TAU or TAU alone. After the intervention period, 
all outcomes (cognitive, functional, acceptability) were repeated at 
a post-intervention assessment (week 13) and a follow-up assess-
ment 12 weeks later (week 25).11 Each assessment was conducted 
in a private, quiet room and was only undertaken where partici-
pants had capacity to consent and complete the assessments. 
Participants were instructed to sleep well (as much as possible) the 
night before assessments and to entirely avoid use of alcohol or 
non-prescribed drugs on the day of assessments. Cognitive tests 
were undertaken as close as possible to 1-4 PM to standardise 
daily fluctuations in alertness.
2.6 | Outcomes
As detailed in the protocol, the four main feasibility outcomes were 
considered primary with equal weighting. These, and the measures 
used to examine them, were:
1. Trial feasibility: recruitment (number consenting to participate) 
and completion (number completing the final outcome assess-
ment) rates assessed acceptability of randomisation to TAU 
relative to CRT. No specific criteria were set a priori to de-
termine sufficient feasibility (recruitment/ completion rates) to 
progress the research to a comprehensive future trial.
2. CRT intervention acceptability: the number of participants com-
pleting 20 hours of CRT, average number of hours completed, 
and CRT satisfaction questionnaire ratings.17 Time spent in ses-
sions with a therapist and independent CIRCuiTS practice were 
summed to calculate completion time. Service use and health-
related quality-of-life were assessed for health economic analyses 
(for details, see Statistical Analysis section below).14,18
3. Cognitive outcomes: the cognition battery measured processing 
speed, attention (digit symbol substitution test [DSST], symbol 
search test [SS]) and working memory (digit span [DS]),19 verbal 
learning (verbal paired associates I [VPA1]) and memory (verbal 
paired associates II [VPA2]),20 current IQ [WASI],21 verbal fluency 
[FAS],22 executive function [Hotel test]23 and perceived cogni-
tive impairment (perceived deficits questionnaire [PDQ]).24 A 
composite score of cognitive function (processing speed, working 
memory, verbal memory, verbal fluency, IQ, executive function 
domains) was calculated to examine global cognition.11 Of these, 
the DSST was proposed as a potential primary outcome for a fu-
ture efficacy CRT trial because it has shown high sensitivity to 
change over time.19 Although IQ is commonly considered a stable 
trait the WASI assessment has been validated to show variability 
over time and is commonly used as a “current intellectual func-
tioning” tool.21 The cognitive tests and the UPSA (below) have 
known practice effects, thus it was expected that improvements 
would be observed over time across the sample and between-
groups comparisons addressed this to indicate relative perfor-
mance between those randomised to TAU vs CRT.
4. Functional outcomes: functional capacity (UCSD performance-
based skills assessment [UPSA]),25 psychosocial functioning 
(functioning assessment short test [FAST])26 and achievement of 
patient-defined goals (goal attainment scale[GAS]).27 FAST uti-
lises a semi-structured interview to rate level of functioning in the 
domains of autonomy, financial, interpersonal, leisure, cognitive 
and occupational functioning (denoted forthwith as “psychosocial 
functioning”).
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Additionally, symptoms of depression12 and mania13 were moni-
tored and adverse events recorded throughout.
2.7 | Statistical analysis
The target sample size of 60 was selected due to recommendations 
for pilot trials to estimate efficacy.28 All planned analyses adopted 
the intention-to-treat (ITT) approach. As detailed in the protocol11 
descriptive statistics summarized participant characteristics as ap-
propriate (mean, standard deviation [SD], median, interquartile 
range [IQR], frequency and percentage [%]). Inferential statistics 
produced group differences and standardised effect sizes (SES) with 
confidence intervals (95% CI) computed using R version 3.6.1.29
2.7.1 | Outcome 1—Trial feasibility
Descriptively, the rate of consenting eligible participants, assess-
ment non-completion and study withdrawals were examined along-
side reasons for each trial arm.
2.7.2 | Outcome 2—CRT intervention acceptability
Descriptive statistics examined intervention acceptability (CRT sat-
isfaction questionnaire)17 and feasibility (number of participants 
completing 20 therapy sessions, total hours engaged with therapy, 
reasons for non-engagement). A health and social care perspective 
was adopted in the cost-effectiveness. The economic costs of CRT 
and TAU services were calculated; service-use during the trial was 
measured by the CSRI14 and combined with standard unit costs of 
these services30 added to intervention costs (the resources required 
to deliver CIRCuiTS, eg, therapist time, overheads). These were com-
bined with quality-adjusted life years derived from the EQ-5D-3L18 
using area under the curve methods to compare groups.11
2.7.3 | Outcomes 3 and 4—putative effects of CRT 
on cognition and function
Intervention effect sizes (ES) were estimated using linear mixed mod-
els for each outcome measurement at both post-treatment (week 13) 
and follow-up (week 25) with outcome timepoint as dependent vari-
able plus fixed effects of trial arm (CRT vs TAU) and baseline meas-
ures of outcome. Standardised effect sizes (SES) and 95% CI were 
calculated by dividing the group mean differences by standard de-
viation of the baseline outcome score. The following convention was 
used to interpret effect size: small 0.2-0.49, moderate 0.5-0.79, large 
≥0.8. As a pilot study, estimation is focused on ES but includes p-
values as an aid to interpretation. Missing data were dealt with using 
a maximum likelihood (ML) approach with the missing at random 
(MAR) assumption. Baseline predictors of missingness were sought, 
to be included in the analysis model if an association was found at a 
liberal P < .2 criterion. The study was monitored by a Trial Steering 
Committee and the trial was pre-registered in the ISRCTN registry 
(ID32290525; http://www.isrctn.com/ISRCT N3229 0525).
2.8 | Changes to the protocol
Compared to the published protocol, minor changes since trial com-
mencement are as follows:
1. Diagnostic subtype: only patients with bipolar disorder type 
I were eligible. From November 2016 (recruitment month 9, 
after n = 25), eligibility was broadened to include individuals 
with BD type II in response to lack of evidence suggesting 
cognitive differences between diagnostic subtypes.2
2. Sub-analyses: We had planned to analyse differences in cognition 
over the menstrual cycle but many patients were not currently 
menstruating and therefore these analyses were not included.
3. Functional capacity: A practical test of functioning was added to 
the outcome assessment protocol prior to trial commencement, 
to assess function using an applied measure. The UPSA25 is a rec-
ommended outcome measure in cognitive trials due to its mod-
erate correlations with cognitive performance and psychosocial 
functioning.31
3  | RESULTS
Between 02/2016 and 06/2018, 60 participants were recruited and 
randomised (CRT n = 29, TAU n = 31) and included in analysis. The 
CONSORT diagram delineates the flow of participants throughout 
the trial (Figure 1).
Participant characteristics (Table 1) indicate overall comparabil-
ity between CRT and TAU groups. The sample consisted mostly of 
women (68%; CRT 72%, TAU 65%) with a median age of 42 (IQR; 
31-52). Most participants met diagnostic criteria for type I BD (70%; 
CRT 69%, TAU 71%) and the remaining for type II. Participants were 
taking a median of two psychotropic medications, most commonly 
antipsychotics and approximately half the sample reported a physi-
cal health condition and were taking non-psychotropic medication. 
Clinical characteristics are displayed in Appendix Table A1.
4  | TRIAL FE A SIBILIT Y
4.1 | Recruitment rate
A mean of 2.3 participants per month were recruited and consented 
into the trial (SD = 0.97, range 0-5). For a sample size of 60, 226 po-
tential participants were identified, giving a recruitment rate of 36% 
(95% CI [29%, 44%]). The most common reason for non-participation 
was inability to commit to appointments at the research site multiple 
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times per week for 12 weeks for CRT, most frequently due to long 
travel distances required to attend.
4.2 | Completion rate
Of the 60 individuals randomised, seven participants (12%, 95% 
CI [5%, 22%]) were lost to follow-up due to withdrawal (n = 6) or 
contact loss (n = 1). The odds of dropout were non-significantly 
higher in TAU (n = 5) than CRT (n = 2) groups; OR = 2.31, P = .44. 
Withdrawal immediately after randomization occurred for one CRT 
participant (life events) and two TAU participants (one unsatisfied 
with randomization to TAU; one life events). Loss at follow-up dur-
ing the intervention period occurred for one CRT participant (illness) 
and three TAU participants (one sought other cognitive interven-
tion; one illness; one contact loss). All other participants attended all 
assessments: unless specified, all analyses include all participants. 
No demographic or clinical baseline predictors of missing data were 
identified (all P > .25).
4.3 | Intervention feasibility
4.3.1 | CRT completion
22/29 participants completed >20 hours of therapy (76%). Including 
all 29 participants, a mean of 25 (SD = 13, range 0-48) CRT hours 
were completed. The 22 completers undertook a mean of 31 hours 
(SD = 7, range 22-48). Of the seven non-completers, two with-
drew from the trial (described above), one was considered to have 
a substance-use disorder (deviation from protocol) during CRT 
which impeded engagement (10-19 therapy hours). The other four 
participants were allocated the same therapist: this therapist was 
subsequently found to not comply with study protocols (including 
F I G U R E  1   CONSORT diagram. *26 participants received at least some CRT therapy. The two participants who did not complete any 
therapy plus two who completed < 10 hours CRT had the same therapist who did not engage with the study. One further participant 
was identified subsequently as meeting an exclusion criterion for the study (10-19 hours therapy). These five individuals were subject to 
sensitivity analysis for cognitive and functional outcomes because they were considered to not have been treated in full adherence to the 
protocol, unlike other participants (including those who withdrew, who were not excluded in per-protocol analyses)
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adherence to treatment guidelines and timely communications with 
participants), which was thus considered a protocol deviation. Of 
these four participants, two did not begin therapy and two com-
pleted <10 hours. These five participants whose participation in the 
trial were considered to deviate from the original protocol were sub-
ject to sensitivity analysis (N = 55 is referred to as “per-protocol,” 
N = 60 as “ITT analysis”).
4.3.2 | CRT satisfaction
The satisfaction questionnaire (n = 21) indicated acceptabil-
ity (Appendix Table A2); 95% said they improved after CRT, 86% 
felt there were the right number of sessions and 100% liked their 
therapist. 76% agreed that CRT made them more aware of their 
limitations; all rated increased awareness as helpful rather than frus-
trating. Health economics: Service use was similar between groups 
although treatment costs were non-significantly higher for those 
receiving TAU. This was the case before accounting for CRT costs 
(week 0: TAU £1,880 and CRT + TAU £1,744 (£135 higher, 95% CI 
[-£1873, 1221]); week 13, TAU £809, CRT + TAU £794 (£16 higher, 
95% CI [-£498, 459]), week 25 TAU £649, CRT + TAU £618 (£32 
higher, 95% CI [-£314, 251]) and after CRT costs (£629.70 per partici-
pant) were added to usual care during follow-up (CRT £2082, TAU 
£1458; 95% CI difference [−£80, £1238]). Health-related quality-
of-life improved slightly between weeks 0 and 13 similarly between 
TA B L E  1   Participant characteristics at baseline
Variable Labels TAU (n = 31) CRT (n = 29)
All 
(N = 60)
Age med (IQR) 42.5 (31.8, 52.2) 43 (34, 52.5) 42 (31, 52)
Gendera  Male n (%) 11 (35.5) 8 (27.6) 19 (31.7)
Female n (%) 20 (64.5) 21 (72.4) 41 (68.3)
Ethnicity White British n (%) 21 (67.7) 17 (58.6) 38 (63.3)
Black British n (%) 1 (3.2) 1 (3.4) 2 (3.3)
Asian British n (%) 1 (3.2) 2 (6.9) 3 (5)
White Other n (%) 5 (16.1) 7 (24.1) 12 (20)
Non-White Other 
n (%)
3 (9.7) 1 (3.4) 4 (6.7)
Mixed n (%) 0 (0) 1 (3.4) 1 (1.7)
Employment Employed n %) 15 (48.4) 13 (44.8) 28 (46.7)
Unemployed n (%) 13 (41.9) 13 (44.8) 26 (43.3)
Retired n (%) 3 (9.7) 3 (10.3) 6 (10)
Education (yrs) med (IQR) 16 (15, 17) 16 (15, 17) 16 (14, 18)
BMI med(IQR) 28 (26, 32) 27 (24, 30) 27 (25, 31)
Physical health condition n (%) 13 (42) 18 (62) 31 (52)
Bipolar diagnosis Type I n (%) 22 (71) 20 (69) 42 (70)
Type II n (%) 9 (29) 9 (31) 18 (30)
Current psychotropic medications Total number med 
(IQR)
2 (2, 3) 2 (2, 3) 2 (2, 3)
Lithium n (%) 14 (45.2) 7 (24.1) 21 (35)
Anticonvulsants n (%) 18 (58.1) 17 (58.6) 35 (58.3)
Antipsychotics n (%) 24 (77.4) 21 (72.4) 45 (75)
Antidepressants 
n (%)
15 (48.4) 13 (44.8) 28 (46.7)
Current non-psychotropic 
medications
 n (%)  12 (38.7)  15 (51.7)  27 (45
 Months in current euthymia  med (IQR)  5 (2, 13.5)  6 (2, 15)  4 (2, 12) 
 Total number of episodes  med (IQR)  13.5 (8, 24.2)  13 (8, 20.5)  15 (8, 30)
Depression severity (HAMD) med (IQR) 3 (1, 5.5) 4 (3, 7) 4 (2, 6)
Mania severity (YMRS) med (IQR) 1 (0, 3) 2 (1, 4) 1 (0, 4)
Abbreviations: BMI, body mass index; CRT, cognitive remediation therapy; HAMD, Hamilton rating scale for depression 17-item version; IQR, 
interquartile range; med, median; TAU, treatment as usual; YMRS, Young mania rating scale.
aGender was determined by asking patients their gender (as an open-ended question); all responded as male/man or female/woman. 
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groups. QALY values accrued over the follow-up period were similar 
(CRT + TAU mean = 0.40, SD = 0.09; TAU mean = 0.41; SD = 0.07); 
with little difference after controlling for baseline (−0.002; 95% CI 
[−0.035, 0.032]). Overall, CRT + TAU resulted in non-significantly 
higher overall costs and slightly fewer QALYs and was therefore 
“dominated” by TAU alone. However, there was much uncertainty 
around the estimates.
4.4 | Putative cognitive effects of CRT
Table 2 displays cognitive and functioning scores throughout the trial. 
At baseline, 40 (67%) of patients scored ≥0.5 SD below the norma-
tive mean in two or more individual cognitive tests; the proportion of 
patients impaired according to recommended definitions31 are pre-
sented in Table 2 alongside raw scores. Cognitive outcome analyses 
are displayed in Table 3: Both groups improved between baseline 
and subsequent assessments. Both mean difference effect sizes 
after treatment (see also Appendix Table A3), and linear mixed mod-
els (Table 3), demonstrated greater improvements in the CRT than 
TAU groups. Linear mixed models indicated that CRT participants 
showed larger improvements than TAU participants at both post-
treatment (week 13) and follow-up (week 25) for IQ (WASI: week 13 
SES = 0.52, 95% CI [0.10, 0.94], P = .015; week 25 SES = 0.71, 95% 
CI [0.29, 1.13], P = .001), working memory (DS: week 13 SES = 0.45, 
95% CI [0.06, 0.84], P = .024; week 25 SES = 0.70, 95% CI [0.31, 
1.10], P = .001) and executive function (Hotel: week 13 SES = 0.68, 
95% CI [0.08, 1.28], P = .027; week 25 SES = 0.93, 95% CI [0.33, 
1.54], P = .003). Additionally, this effect was observed at week 
25 for global cognition (composite test: SES = 0.68 95% CI [0.28, 
1.06], P = .001), memory recall (VPA2: SES = 0.45, 95% CI [0.13, 
0.78], P = .007), verbal fluency (FAS: SES = 0.52, 95% CI [0.17, 0.86], 
P = .004) and processing speed (DSST: SES = 0.35, 95% CI [0.03, 
0.67], P = .031 and SS: SES = 0.66, 95% CI [0.25, 1.06], P = .002). 
Figure 2 depicts cognitive changes between groups as analysed by 
linear mixed models.
4.5 | Putative functional effects of CRT
At baseline, 27 (55%) of participants were categorised as having 
moderate to severe impairments in functioning while 33 (45%) had 
no or mild functional impairment, according to validated FAST cut-
off scores32 (see Table 2). Similar to cognition, between-group ef-
fect sizes indicate larger improvements in CRT than TAU participants 
on functional measures (Table 2). Linear mixed models (see Table 3) 
identified significantly greater improvements at weeks 13 and 25 for 
psychosocial functioning (FAST: week 13 SES = 0.45, 95% CI [0.15, 
0.76], P = .004; week 25 SES = 0.49, 95% CI [0.18, 0.80], P = .002) 
and goal attainment (GAS: week 13 SES = 3.46, 95% CI [2.33, 4.58], 
P < .001; week 25 SES = 2.02, 95% CI [0.89, 3.14], P = .001). At week 
13 but not 25, functional capacity was more improved in CRT partici-
pants (UPSA: SES = 0.56, 95% CI [0.11, 1.01], P = .015). Sensitivity 
analyses demonstrated consistently greater benefits for per-proto-
col CRT than TAU participants (n = 55) across cognition and func-
tioning at both post-treatment timepoints; see Appendix Table A4.
4.5.1 | Affective symptoms
Symptoms were similar between groups (see Appendix Table A1), 
although participants in the CRT group had slightly higher subsyn-
dromal depression (HAM-D) scores at week 25 (TAU mean = 4, 
SD = 3; CRT mean = 6, SD = 4; ES = 0.59, 95% CI [0.03, 1.15]). No 
full relapses were recorded in participants attending follow-up visits; 
four participants at week 25 had mild depressive symptoms (HAMD 
score 14-15; 3 CRT, 1 TAU) and one participant had mild mania symp-
toms (YMRS 20; TAU participant).
4.5.2 | Adverse events
No serious adverse events occurred. Four adverse events were re-
corded, each for different participants, related to study procedures 
(experience of distress at feeling they performed poorly on cognitive 
tests, n = 2) or bipolar illness (depressive episode, n = 2). No suicide 
attempts or self-harm were disclosed to the study team.
5  | DISCUSSION
These results indicate high feasibility and acceptability of individual, 
therapist-led CRT using the established CIRCuiTS programme, as a 
potential treatment to enhance cognition and functioning for BD, 
with promising effect sizes on cognitive and functional outcomes.
5.1 | Feasibility and acceptability
The ADePT (Decision-making after Pilot and feasibility Trials) pro-
cess aims to stimulate systematic identification and consideration of 
problems and solutions arising from feasibility trials and enhance the 
decision-making process in progressing to future studies.33 While a 
priori progression criteria appear optimal, ascertaining the potential 
for progression post-hoc is often more appropriate to maximise com-
parability between the present trial findings and the most relevant, 
high-quality research published to date. For example, cognitive trial 
recommendations31 and the only randomised individual CRT trial 
for BD9 were not available by the time of CRiB protocol finalisation. 
ADePT considers issues related to whether it is feasible to achieve 
adequate power in a future efficacy trial based on sample size cal-
culations using effect sizes indicated from pilot trial outcomes: We 
report mostly medium ES in line with previous work.9 Achieving ade-
quate power also relies on the feasibility of meeting recruitment tar-
gets by identifying sufficient participants who are eligible and willing 
to consent (in CRiB, similar to previous trials9,10,15), the number of 
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TA B L E  2   Cognitive and functional measures at all time points
Test N (%) ≥0.5 SD below meana  Arm
Baseline (Week 0) Post-treatment (Week 13) Follow-up (Week 25)
Median (IQR) Median (IQR) Median (IQR)
DSST 24 (40%) All 62 (53.75, 75.25) 64 (59, 78) 69 (59, 79)
TAU 61 (53.5, 73.5) 63.5 (56.5, 76.25) 65.5 (58, 77.5)
CRT 63 (54, 76) 67 (60, 79) 74 (60, 85)
WASI 12 (20%) All 109 (97.5, 113.5) 109 (101, 119) 112 (101, 118)
TAU 106 (94, 110) 103 (98.5, 113.75) 103 (100, 112.75)
CRT 111 (104, 117) 117 (106.5, 122) 116 (109.5, 124)
VPA1 25 (42%) All 29 (20.75, 39.25) 33 (22, 47) 41 (30, 50)
TAU 25 (17.5, 34.5) 30 (22, 47.5) 33 (25.5, 45)
CRT 36 (26, 43) 38 (26.5, 47) 49 (35.5, 52)
VPA2 recall 30 (50%) All 8.5 (6.75, 13) 10 (7, 13) 12 (9, 14)
TAU 8 (5.5, 11.5) 9 (6, 12) 9.5 (7, 12)
CRT 11 (7, 13) 12 (8.5, 14) 13 (10, 14)
VPA2 recognition 20 (33%) All 39 (36, 40) 40 (38, 40) 40 (39, 40)
TAU 38 (35, 40) 39 (37, 40) 39 (37.3, 40)
CRT 39 (37, 40) 40 (38.5, 40) 40 (39, 40)
DS 9 (15%) All 27 (25.75, 32) 29 (27, 32) 30 (27, 32)
TAU 30 (25, 33) 29.5 (26.25, 32) 29 (26, 31)
CRT 27 (26, 32) 29 (27, 32.5) 31 (28, 35.5)
SS 18 (30%) All 32 (27, 35.25) 34 (28, 39) 33 (27, 40)
TAU 31 (28, 34.5) 33.5 (26.5, 37.75) 32 (25.75, 36.5)
CRT 33 (26, 37) 34 (29.5, 39) 37 (28, 41.5)
FAS 24 (40%) All 44 (34, 50) 45 (38, 56) 48 (36, 57)
TAU 43 (32.5, 50.5) 42.5 (32.25 57.75) 43.5 (32.5, 54.75)
CRT 46 (37, 50) 45 (39.5 55.5) 49 (41.5, 60.5)
Hotel 32 (53%) All 341.5 (205.5, 541) 240 (132, 288) 166 (79.5, 240)
TAU 304 (168, 508) 251 (153.25, 380) 198 (95.5, 300.25)
CRT 406 (248, 568) 164 (114, 261) 98.5 (67, 207.5)
Global 22 (37%) All 2.8 (2.51, 3.26) 3.2 (2.71, 3.51) 3.2 (2.83, 3.67)
TAU 2.8 (2.35, 3.14) 3.0 (2.60, 3.32) 3.1 (2.69, 3.38)
CRT 3.00 (2.58, 3.32) 3.2 (2.89, 3.72) 3.6 (3.06, 4.00)
PDQ n/a All 36 (27, 44) 30 (20, 37) 30 (19, 39)
TAU 35 (25.5, 44.5) 29.5 (17, 41) 31 (12.75, 37.75)
CRT 37 (28, 43) 31 (21, 36.5) 30 (20.5, 40.5)
UPSA n/a All 74 (67, 81.75) 81 (72, 86) 84 (74, 93)
TAU 71.5 (65.75, 82.25) 78 (68, 86) 80 (74, 88)
CRT 74 (69.75, 81.75) 81 (79, 86) 86 (81, 93)
FAST n/a All 21.5 (13, 29.25) 20 (11, 29) 22 (11, 28)
TAU 19 (12.5, 26) 19 (13.25, 26.75) 21.5 (13, 26.5)
CRT 25 (15, 32) 22 (10, 29) 22 (10.5, 29)
GAS n/a All 36.4 (31.13, 37.6) 44.9 (38.8, 52.05) 45.9 (39.65, 54.9)
TAU 36.5 (31.15, 37.6) 39.9 (32.4, 44.2) 42.2 (36.8, 47.3)
CRT 34.6 (30.97, 37.6) 51.2 (45.17, 60.53) 51.5 (43.95, 57.1)
Bold values are used to highlight the rows which contain all participants, those not in bold are the subsamples split by randomisation group.
Abbreviations: DS, Digit Span; DSST, Digit Symbol Substitution Test; FAS, verbal fluency test; FAST, Functioning Assessment Short Test; GAS, goal 
attainment scale; PDQ, perceived deficits questionnaire; SS, Symbol Search; UPSA, UCSD Performance-based Skills Assessment; VPA, Verbal Paired 
Associates; WASI, IQ.
aProportion impaired compared to demographically-corrected normative values. All other cognitive data are presented as raw scores. 
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patients engaged with intervention and completing the trial (CRiB 
being equivalent or better compared to previous similar studies9,14,34 
with its 12% loss to follow-up rate and high therapy completion rate) 
between the number of required sites (multisite differences not as-
sessed in the single-site CRiB study). In addition, we did not expe-
rience issues with key aspects of the trial design (randomisation, 
blinding) or cost and duration of intervention (with health economic 
analyses indicating non-significant service use/QALY differences 
between CRT and TAU groups). Outcome selection was also in ac-
cordance with taskforce recommendations31; thus taken together, 
our findings suggest an efficacy trial of CRT for BD is both feasible 
and justified in terms of its putative benefits to patients.
The CRT satisfaction questionnaire indicated high acceptabil-
ity, which we aim to examine more comprehensively in qualitative 
analyses for understanding and potentially refining the CIRCuiTS 
treatment manual tailored to people with BD. Five non-completers’ 
participation deviated from the trial protocol (one due to ineligibil-
ity, four whose therapist did not adhere to protocols). Sensitivity 
analyses removing these participants indicate somewhat higher ES 
after they were removed. The protocol deviations alone suggest that 
patients with active substance-use disorders should be advised to 
seek help for this before undertaking CRT and emphasises the need 
to prioritise therapist adherence to protocols when designing future 
trials (ie, carefully consider therapist selection to ensure their adher-
ence to study and treatment protocols, and engagement with par-
ticipants). After excluding the protocol-deviation participants, the 
therapy completion rate was 93% (7% study withdrawals due to ill-
ness or life events) which indicates very high feasibility of CIRCuiTS. 
Minimal adverse events also imply safety. Future efficacy studies 
should examine the long-term cost-effectiveness of CIRCuiTS vs 
TAU in the months and years following therapy completion, as is 
being undertaken for individuals with psychosis35; if inpatient ad-
missions are reduced this would certainly indicate promising cost- 
effectiveness of the intervention.
5.2 | Putative effects of CRT
Despite a relatively small sample size, large effects on cogni-
tion and functioning were observed, enduring for three months 
after the end of therapy. These are similar to effects observed 
in CRT for schizophrenia5,6 and equivalent9 or greater than10,34 
previous BD trials. As reported in recent systematic reviews3,4 
a handful of studies investigating related interventions for BD. 
A distinct intervention focusing on functional rather than cogni-
tive remediation has been supported in a randomised trial finding 
small benefits in functioning compared to psychoeducation treat-
ment.34 Specific CRT programmes have been tested in 4 studies. 
Initially, one open-label study reported cognitive and clinical im-
provements particularly for participants less cognitively impaired 
at baseline (N = 18).36 Conclusions are limited by the single-arm 
study design but this promoted CRT’s potential for this popula-
tion. Two subsequent group-CRT studies followed; one natural-
istic study reporting non-significant cognitive benefits (N = 26) 
37 and a randomised study finding benefits to subjective but not 
objective cognitive tests.10 The group CRT studies conclude that 
more intensive, therapist-led individual CRT emphasizing meta-
cognitive skills and strategy use would likely yield meaningful 
TA B L E  3   Cognitive and functional outcomes between CRT and TAU (time x group interactions)
Measure
Week 13 Week 25
SES (95% CI) t (df) P SES (95% CI) t (df) P
Processing speed/
attention
DSST 0.25 (−0.07, 0.57) 1.57 (69.8) 0.122 0.35 (0.03, 0.67) 2.2 (69.8) 0.031
SS 0.26 (−0.15, 0.67) 1.25 (93.5) 0.213 0.66 (0.25, 1.06) 3.19 (93.5) 0.002
Working memory DS 0.45 (0.06, 0.84) 2.3 (78.1) 0.024 0.7 (0.31, 1.1) 3.59 (78.1) 0.001
Verbal learning VPA1 −0.07 (−0.48, 0.35) −0.33 (74.8) 0.745 0.32 (−0.1, 0.73) 1.53 (74.8) 0.13
Verbal memory Recall 0.29 (−0.03, 0.62) 1.8 (69.9) 0.077 0.45 (0.13, 0.78) 2.76 (69.9) 0.007
Recognition 0.17 (−0.57, 0.91) 0.46 (97.4) 0.648 −0.2 (−0.94, 0.54) −0.54 (97.4) 0.594
IQ WASI 0.52 (0.1, 0.94) 2.48 (75.7) 0.015 0.71 (0.29, 1.13) 3.39 (75.7) 0.001
Verbal fluency FAS 0.14 (−0.21, 0.48) 0.80 (83.1) 0.428 0.52 (0.17, 0.86) 2.99 (83.1) 0.004
Perceived deficits PDQ 0.06 (−0.44, 0.57) 0.24 (70.8) 0.811 0.18 (−0.33, 0.68) 0.71 (70.8) 0.483
Executive function Hotel −0.68 (−1.28, −0.08) −2.25 (68.8) 0.027 −0.93 (−1.54, −0.33) −3.08 (69.7) 0.003
Global cognition Composite 0.17 (−0.23, 0.57) 0.86 (85.3) 0.391 0.68 (0.28, 1.06) 3.36 (86) 0.001
Functional capacity UPSA 0.56 (0.11, 1.01) 2.47 (78.6) 0.015 0.33 (−0.12, 0.79) 1.47 (79.3) 0.147
Psychosocial 
functioning
FAST −0.45 (−0.76, −0.15) −2.95 (65.1) 0.004 −0.49 (−0.8, −0.18) −3.19 (65.1) 0.002
Goal attainment GAS 3.46 (2.33, 4.58) 6.14 (61.2) <0.001 2.02 (0.89, 3.14) 3.58 (61.2) 0.001
Abbreviations: CI, confidence interval; df, degrees of freedom; DS, Digit Span; DSST, Digit Symbol Substitution Test; FAS, verbal fluency test; FAST, 
Functioning Assessment Short Test; GAS, goal attainment scale; PDQ, perceived deficits questionnaire; SES, standardised effect size; SS, Symbol 
Search; UPSA, UCSD Performance-based Skills Assessment; VPA1, Verbal Paired Associates I; WASI, IQ.
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(cognitive and functional) benefits. These were key elements of 
the CIRCuiTS therapy in this trial and the larger effects that we 
report compared to previous BD studies may be attributable to 
this. This speculation is supported further by the reports from 
the only other randomised trial examining individual CRT for in-
dividuals with BD, whose CRT intervention consisted of inten-
sive training with multiple weekly sessions over 24 weeks.9 This 
randomised trial was for patients with psychotic bipolar disorder, 
representing a slightly different population to CRiB, but reported 
similar medium/high effect sizes to those we present here.9 
Together, the extant studies support the use of time-intensive in-
dividual cognitive remediation for people with BD but a focus is 
needed on therapy components in upcoming studies.
Some cognitive improvements were not evident in our study; 
notably the participants’ perceived deficits, which contrasts 
somewhat with CRT satisfaction responses and objective perfor-
mance tests, but possibly reflects an increased awareness of in-
dividuals’ own cognitive weaknesses after CRT (especially given 
the metacognitive focus of the intervention). Other CRT pro-
grammes trialled for BD have not emphasised metacognitive skill 
development and have either not assessed subjective cognitive 
impairments9 or reported subjective improvements in the absence 
of objective cognitive improvements after CRT.10 In the original 
study protocol, the putative primary outcome was the DSST test 
of processing speed and attention due to its reported sensitivity to 
change. At follow-up, this was significantly improved by CRT, with 
F I G U R E  2   cognitive outcomes after CRT and TAU. Effect size (time x group interactions) at week 13 and week 25 compared to pre-
treatment cognitive performance. * The Hotel test was reverse-scored, meaning that a negative effect size represents greater improvement. 
Abbreviations: DSST = Digit Symbol Substitution Test (processing speed and attention), SS = Symbol Search (processing speed and 
attention), DS = Digit Span (working memory), VPA1 = Verbal Paired Associates (verbal learning), WASI = IQ, FAS = verbal fluency test, 
PDQ = perceived deficits questionnaire (subjective deficits), Hotel = hotel test of executive function, Global = composite measure of 
cognitive function
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similarly large ES observed in working memory, IQ and executive 
function. The IQ improvement, although a validated two-subtest 
measure, may have been driven by the matrix reasoning rather 
than vocabulary subtest in the WASI; matrix reasoning is a visual 
problem solving task which could reflect executive functions and 
be more susceptible to change than vocabulary domain. It may 
be that CRT targets on executive function are particularly vital 
for transfer of gains from cognition to everyday functioning, as 
has been found for people with schizophrenia.38 Goal attainment 
yielded the largest effect size, whose size may be attributable to 
participants creating personally meaningful cognitive and func-
tional goals that would have been directly and explicitly targeted 
in therapy. However, assessments of functioning are likely to be 
associated with cognition: both the FAST (which includes a do-
main of cognitive functioning in everyday situations) and the GAS 
(where participants’ goals may relate to cognitive functioning). 
Inter-correlations between individual cognitive tests should also 
be considered, as in all neuropsychological batteries, due to mea-
surement of overlapping domains.
5.3 | The influence of pre-existing 
cognitive impairment
For populations with psychosis, CRT benefits appear more pro-
nounced for individuals with more extensive pre-existing cogni-
tive impairments and it is widely recommended to recruit only 
participants with existing deficits. For individuals with BD this 
is not supported by the existing literature and enhancing cogni-
tion appears to be beneficial in terms of quality-of-life even for 
those without cognitive scores below demographically-corrected 
normative values. This is supported by current findings; at base-
line, over one third of the CRiB sample scored >0.5 SD below 
the mean global composite measure and two thirds scored low 
on at least two individual cognitive tests, which is comparable 
to previous literature focusing on rates of cognitive impairment 
in those with BD.2 The CRiB sample size is insufficient to exam-
ine whether existing cognitive impairments affected subsequent 
improvement; future trials should assess whether CRT is recom-
mended for those without deficits. The same is true when con-
sidering functional impairment; the data reported here indicate 
that the participants recruited in the CRiB study were represent-
ative in terms of cognition and functioning compared to other 
published samples (with 55% showing moderate or severe func-
tional impairment, in comparison with 51% previously reported 
using these FAST severity cut-offs).32
5.4 | Strengths and limitations
Notable strengths of this study include trial preregistration, a low 
proportion of missing data, the use of intention-to-treat analyses, 
stringent randomisation, and blinding of assessment researchers. 
The ability to determine benefits of CRT are limited by the feasibil-
ity nature of the study and correspondingly small sample size. The 
sample size prevented a more in-depth examination of the effects of 
CRT; we were unable to adjust for factors known to influence cogni-
tion such as various medications (psychotropic and somatic), physical 
illness, and sleep quality. We stratified randomisation based on the 
intensity of usual care patients received at baseline, which balanced 
TAU between groups; however, there is at present little justification 
for taking this decision in a future trial and stratifying based on cogni-
tive impairment would likely be more beneficial, not least for ensur-
ing that baseline impairment is well balanced between randomisation 
allocations. In this trial, CRT/TAU groups showed little difference on 
cognitive or functional variables except that verbal recall perfor-
mance was better in the CRT group at baseline (ES = 0.6 and was 
one of the few domains which did not show a relative improvement 
in CRT compared with TAU participants at follow-up). This occur-
rence can happen in small trials and is addressed through adjusting 
for baseline performance in linear mixed models, but one would ex-
pect poor performance to precede higher effect sizes based on the 
notion of “room for improvement.”31 This is an assumption made in 
recommendations for trials to recruit only cognitively impaired in-
dividuals; namely the ISBD taskforce recommendations which were 
not available at the time of CRiB initiation; however, more evidence 
to support or refute this is certainly warranted. It is also worth not-
ing that cognitive assessments (and the UPSA) have known practise 
effects which were addressed through between-group comparisons 
and baseline adjustment in linear mixed models. The results of this 
RCT require replication in larger, more definitive trials with multi-
ple sites (since single studies such as CRiB limit generalisability of 
findings). Our participants were predominantly white, British and 
educated; more diverse samples are needed in future trials to better 
represent BD populations and improve generalisability of results. We 
recommend that these trials also seek to establish the core therapeu-
tic components of CRT, the role of metacognitive skill development 
and whether there is a “target” group of patients with BD who would 
confer the most meaningful and enduring benefits from CRT, which 
would obviate unnecessary resource-intensive studies. In the current 
study, outcome assessors were instructed to disclose any incidents 
of inadvertent unblinding and an alternative assessor undertook 
these outcome assessments. Because procedures for recording and 
addressing incidents of unblinding were not formalised, it cannot be 
confirmed whether any assessments were undertaken by assessors 
who might have suspected which group the participant had been al-
located to. Future trials should therefore formally assess whether, 
despite blinding, inadvertent beliefs about which trial arm partici-
pants were allocated could influence trial outcomes.
5.5 | Future implications
While current clinical practice commonly uses pharmacological treat-
ments targeting acute affective symptoms, clinical evidence39 and 
our engagement work indicates that service users desire additional 
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psychological therapies which may enhance quality-of-life more 
broadly. CIRCuiTS may be a good candidate to address these needs. 
Previous examination of CRT for bipolar disorder is limited and re-
ports mixed findings, often from non-randomising studies or using 
less evidence-based programmes.1 The CRiB study sought to fill 
this evidence gap in setting a precedent for future work to establish 
whether this intervention has real potential for people with BD via 
efficacy and mechanistic trials. Considering the present findings, we 
urge future CRT studies to use robust methodology and manualised 
interventions to advance comprehension of the putative benefits of 
CRT and accumulate good-quality evidence to inform clinical practice.
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APPENDIX A
Additional information about the CIRCuiTs intervention
The CIRCuiTs intervention has been described in detail previously 
(eg, Reeder & Wykes, 2010; Drake et al, 2014; Reeder et al, 2016). 
Other specific details about the intervention are reported in the 
CRiB study's protocol paper (Strawbridge et al, 2016).
The “Computerised Interactive Remediation of Cognition—
Interactive Training for Schizophrenia” (CIRCUITS) software runs 
from a secure website via an Internet browser. It does not collect or 
contain personally identifiable information about users.
CIRCuiTs is based on a CRT manual validated for patients with 
schizophrenia and uses an engaging interface laid out as a village 
environment guiding participants through a sequence of tasks. 
The tasks notionally take place in locations within the village (for 
example, an executive function shopping exercise in the super-
market). This social context may enhance engagement and/or 
promote explicit application to participants’ everyday lives. There 
are 36 exercises requiring a range of cognitive skill combinations. 
Importantly, the initial exercises require can be achieved by those 
with high cognitive deficits and become more difficult gradually. 
Metacognitive information and exercises, including scaffolding*, 
prepare the user for achieving subsequent levels of increased dif-
ficulty and complexity.
The computerised programme was developed incorporating 
restorative approach to remediation (massed practice of tasks in-
creasing in difficulty) intertwined with compensatory approaches 
that focus on metacognitive skills (ie, individuals’ metacognitive 
knowledge of their own strengths and weaknesses as well as more 
general understanding of how cognition can influence other behav-
iours) and the use of strategies to enhance cognitive functioning. 
The computerised programme aids utilisation of these approaches, 
but the therapist is critical to guide and tailor the remediation pro-
gramme for individuals, and facilitate the transfer of core cognitive 
skills to improve functioning in a range of real-world situations faced 
by patients.
Therapists were qualified to at least Postgraduate level in 
psychology (having achieved undergraduate, Master's and in 
some cases PhD qualification) and knowledge of cognitive mod-
els before undertaking a 2-day specific training in CRT and the 
CIRCUITS programme. Throughout the study they were supported 
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by individual and group supervision sessions with an experienced 
clinical psychologist who had > 5 years experience in cognitive 
remediation therapy.
CIRCuiTs therapy was undertaken utilising a combination of ses-
sion types for all participants, comprising:
a. Face-to-face sessions with a therapist. These usually 
lasted 1 hour but could be as little as 15 minutes or as long 
as 2 hours, depending on the needs and preferences of 
participants;
b. Telephone sessions with a therapist. These could last as little as 
five minutes or as long as one hour depending on the needs and 
preferences of the participants;
c. Independent practice sessions with the computerised system, at a 
location decided upon by the participant. These could last for as lit-
tle or as long as preferred. The time engaged with the computerised 
CIRCuiTs programme was recorded by the system. Therapists also 
encouraged patients to try out strategies in everyday life and routine 
situations, eg, at work which was not possible to fully record and these 
did not contribute to the recorded time engaged with the intervention.
Variable Labels TAU (n = 31) CRT (n = 29)
All 
(N = 60)
Years since bipolar diagnosis (N) med (IQR) 11 (3, 20) 13 (4, 19) 11 (2, 21)
Total number of episodes (N) med (IQR) 13.5 (8, 24.2) 13 (8, 20.5) 15 (8, 30)
Months symptomatic in last year (N) med (IQR) 1.8 (0, 4) 2 (0, 3.5) 1.5 (0, 7)
Months in current euthymia (N) med (IQR) 5 (2, 13.5) 6 (2, 15) 4 (2, 12)
Current psychotropic medications (N) med (IQR) 2 (2, 3) 2 (2, 3) 2 (2, 3)
Meds Ever (N) med (IQR) 6 (4, 9) 6 (4, 9) 6 (4, 9)
Therapy Ever (N) med (IQR) 2 (1, 3) 2 (1, 2.5) 2 (1, 3)
Hospital Admissions (N) med (IQR) 2 (0, 4) 1 (1, 3.5) 2 (0, 4)
Marital status
Single n (%) 15 (48.4) 19 (65.5) 34 (56.7)
Married/Engaged n (%) 14 (45.2) 7 (24.1) 21 (35)
Divorced/Widowed n (%) 2 (6.5) 3 (10.3) 5 (8.3)
Co-habiting
Alone n (%) 8 (25.8) 8 (27.6) 16 (26.7)
Partner n (%) 13 (41.9) 11 (37.9) 24 (40)
As above + children n (%) 5 (16.1) 3 (10.3) 8 (13.3)
Children only n (%) 1 (3.2) 5 (17.2) 6 (10)
House share n (%) 3 (9.7) 1 (3.4) 4 (6.7)
Parents n (%) 1 (3.2) 1 (3.4) 2 (3.3)
Qualifications
None n (%) 0 (0) 1 (3.4) 1 (1.7)
Primary education n (%) 4 (12.9) 5 (17.2) 9 (15)
Secondary education n (%) 9 (29) 11 (37.9) 20 (33.3)
Post-school degree n (%) 13 (41.9) 7 (24.1) 20 (33.3)
Postgraduate degree n (%) 5 (16.1) 4 (13.8) 9 (15)
Doctorate degree n (%) 0 (0) 1 (3.4) 1 (1.7)
Depression severity (HAMD)
Week 0 med (IQR) 3 (1, 6) 4 (3, 7) 4 (2, 6)
Week 13 med (IQR) 5 (2, 7) 5 (3,7) 5 (2,7)
Week 25 med (IQR) 3 (2, 6) 5 (4, 9) 4 (3, 7)
Mania severity (YMRS)
Week 0 med (IQR) 1 (0, 3) 2 (1, 4) 1 (0, 4)
Week 13 med (IQR) 2 (1, 4) 1 (0.5, 5) 2 (1, 5)
Week 25 med (IQR) 4 (2, 6) 3 (2, 4) 3 (2, 5)
Abbreviations: CRT, cognitive remediation therapy; HAMD, Hamilton rating scale for depression, 
17-item version; IQR, interquartile range; med, median; TAU, treatment as usual; YMRS, Young 
mania rating scale.
TA B L E  A 1   Additional characteristics 
of the CRiB sample
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Variable Yes No Other
Did you find the tasks 
difficult?
29% 48% 24% in-between
Did you improve after the 
tasks? a
95% 5%
If improved, did it make you 
feel better?
95% 0 Don't remember: 5%
If not improved, was it 
frustrating?
50% 50% Don't remember: 0
Did the time pass quickly? 90% 0 Don't remember: 10%
Did you like the attention you 
received?
76% 0 Not bothered: 24%
Did it keep your mind 
occupied?
38% 14% Not really: 43% 5% no 
response
Right number of sessions per 
week?
86% Too many: 10%. Too few: 0 5% no response
Did you like your therapist? 100% 0
Was your therapist a good 
teacher?
95% 0 5% no response
Do you think your therapist 
learned anything from you?
14% 24% Hope so: 57%. 5% 
‘don't know’.
Did you miss your therapist 
after CRT ended?
29% 10% Didn't expect to see 
again: 57%. 5% no 
response








Just a therapist: 
19%
5% more complicated. 
10% no response
Did CRT help you get back on 






Not at all: 5%
Did CRT make you more 
aware of your limitations/ 
disability?
76% 10% Don't know: 14%
If yes, was this frustrating? 0 95% 5% frustrating at 
the time but not 
afterwards
Did the effects last beyond 
the therapy?
76% 5% 14% in-between. 5% 
no response
CRT satisfaction questionnaire ratings; N = 21. Bold = options given for response beyond "Yes” 
or “No”. Other answers provided (not in bold) were written by participants outside of options 
provided.
aWhen rating improvement on specific cognitive abilities, participants were asked about the 
permanence of improvements (options were that improvements occurred “at the time” or occurred 
“permanently”: concentration (10 [47%] at the time, 10 [47%] permanently, 1 no response); 
memory (13 [62%] at the time, 7 [33%] permanently, 1 no response); alertness/focus (7 [33%] 
at the time, 9 [43%] permanently, 5 no response). 3 of the participants who rated “permanently” 
acknowledged that therapy had only recently ended and it might not continue. 2 who rated “at the 
time” acknowledged that it might continue. 
TA B L E  A 2   CRT satisfaction ratings
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TA B L E  A 3   Cognitive and functional effect sizes between groups
Variable
ITT analysis (n = 60) Per-protocol analysis (n = 55)
Baseline Week 13 Week 25 Baseline Week 13 Week 25
DSST 0.06 (−0.46, 0.57) 0.22 (−0.34, 0.77) 0.3 (−0.26, 0.85) 0.2 (−0.35, 0.75) 0.49 (−0.1, 1.08) 0.6 (0, 1.19)
WASI 0.39 (−0.13, 0.91) 0.59 (0.03, 1.16) 0.82 (0.25, 1.39) 0.67 (0.11, 1.23) 0.84 (0.23, 1.45) 1.17 (0.54, 1.8)




VPA2 Recall 0.47 (−0.06, 0.99) 0.63 (0.07, 1.2) 0.89 (0.31, 1.47) 0.58 (0.03, 1.14) 0.8 (0.19, 1.4) 1.17 (0.54, 1.8)
VPA2 
Recognition
0.56 (0.04, 1.09) 0.41 (−0.14, 0.97) −0.06 (−0.62, 
0.49)
0.64 (0.08, 1.2) 0.81 (0.2, 1.41) 0.77 (0.17, 
1.38)
DS −0.14 (−0.66, 0.38) 0.32 (−0.23, 0.88) 0.52 (−0.04, 
1.08)












PDQ 0.05 (−0.47, 0.56) 0.15 (−0.4, 0.7) 0.24 (−0.31, 0.8) 0.05 (−0.5, 0.59) 0.01 (−0.57, 0.6) 0.14 (−0.44, 
0.73)
UPSA 0.29 (−0.25, 0.83) 0.58 (0.02, 1.14) 0.46 (−0.1, 1.02) 0.41 (−0.16, 0.99) 0.74 (0.13, 1.34) 0.78 (0.16, 
1.39)
Hotel 0.27 (−0.25, 0.79) −0.54 (−1.1, 0.03) −0.65 (−1.23, 
−0.08)
0.29 (−0.25, 0.84) −0.59 (−1.19, 0) −0.82 (−1.44, 
−0.21)








GAS −0.09 (−0.62, 0.43) 1.56 (0.92, 2.2) 0.86 (0.27, 1.45) −0.01 (−0.56, 
0.54)
1.8 (1.1, 2.5) 1.13 (0.49, 1.76)
Cohen's D (ES and 95% CI) for each cognitive tasks at each timepoint.
Abbreviations: DS, Digit Span; DSST, Digit Symbol Substitution Test; FAS, verbal fluency test; FAST, Functioning Assessment Short Test; GAS, 
goal attainment scale; ITT, intention-to-treat; PDQ, perceived deficits questionnaire; SS, Symbol Search; UPSA, UCSD Performance-based Skills 
Assessment; VPA, Verbal Paired Associates; WASI, IQ.
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